PortalPublikationenBridging INTERMACS 1 patients from VA-ECMO to LVAD via Impel...

Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: De-escalate and ambulate

Standard

Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: De-escalate and ambulate. / Bertoldi, Letizia F; Pappalardo, Federico; Lubos, Edith; Grahn, Hanno; Rybczinski, Meike; Barten, Markus J; Legros, Tim; Bertoglio, Luca; Schrage, Benedikt; Westermann, Dirk; Lapenna, Elisabetta; Reichenspurner, Hermann; Bernhardt, Alexander M.

in: J CRIT CARE, Jahrgang 57, 06.2020, S. 259-263.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Bertoldi, LF, Pappalardo, F, Lubos, E, Grahn, H, Rybczinski, M, Barten, MJ, Legros, T, Bertoglio, L, Schrage, B, Westermann, D, Lapenna, E, Reichenspurner, H & Bernhardt, AM 2020, 'Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: De-escalate and ambulate', J CRIT CARE, Jg. 57, S. 259-263. https://doi.org/10.1016/j.jcrc.2019.12.028

APA

Bertoldi, L. F., Pappalardo, F., Lubos, E., Grahn, H., Rybczinski, M., Barten, M. J., Legros, T., Bertoglio, L., Schrage, B., Westermann, D., Lapenna, E., Reichenspurner, H., & Bernhardt, A. M. (2020). Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: De-escalate and ambulate. J CRIT CARE, 57, 259-263. https://doi.org/10.1016/j.jcrc.2019.12.028

Vancouver

Bertoldi LF, Pappalardo F, Lubos E, Grahn H, Rybczinski M, Barten MJ et al. Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: De-escalate and ambulate. J CRIT CARE. 2020 Jun;57:259-263. https://doi.org/10.1016/j.jcrc.2019.12.028

Bibtex

@article{9913629312564c8db1ac4b4411257ca9,
title = "Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: De-escalate and ambulate",
abstract = "PURPOSE: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) stabilizes patients in refractory cardiogenic shock. However, ECMO-related complications strongly affect the outcome, especially if a long-term LVAD is needed.METHODS AND MATERIALS: We describe a new strategy in management of INTERMACS 1 patients consisting in early weaning from VA-ECMO with axillary Impella 5.0 as a bridge to LVAD implantation. Nine patients in two European centres are described.RESULTS: All patients were implanted with VA-ECMO for initial hemodynamic and metabolic stabilization. After a median time of 8 days, Impella 5.0 was implanted. Impella support allowed in all patients weaning from inotropes and from VA-ECMO (after a median time of 22 h). No patients had right ventricular failure after ECMO-weaning and most patients were mobilized and orally fed (88.9%) during Impella support. All patient underwent LVAD implantation after a median Impella time of 17 days. Only one patient had right-ventricular failure after LVAD implantation. All patients were discharged from hospital after a median time of 40 days.CONCLUSION: Early weaning from VA-ECMO with Impella 5.0 as a bridge to LVAD is a safe and effective strategy in management of INTERMACS 1 patients. This approach minimizes ECMO-related complications and allows patient mobilization and right ventricular function optimization before LVAD implantation.",
keywords = "Adult, Extracorporeal Membrane Oxygenation/instrumentation, Female, Follow-Up Studies, Heart Failure/therapy, Heart-Assist Devices, Hemodynamics, Humans, Male, Middle Aged, Research Design, Retrospective Studies, Shock, Cardiogenic/therapy, Ventricular Function, Right",
author = "Bertoldi, {Letizia F} and Federico Pappalardo and Edith Lubos and Hanno Grahn and Meike Rybczinski and Barten, {Markus J} and Tim Legros and Luca Bertoglio and Benedikt Schrage and Dirk Westermann and Elisabetta Lapenna and Hermann Reichenspurner and Bernhardt, {Alexander M}",
note = "Copyright {\textcopyright} 2019. Published by Elsevier Inc.",
year = "2020",
month = jun,
doi = "10.1016/j.jcrc.2019.12.028",
language = "English",
volume = "57",
pages = "259--263",
journal = "J CRIT CARE",
issn = "0883-9441",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: De-escalate and ambulate

AU - Bertoldi, Letizia F

AU - Pappalardo, Federico

AU - Lubos, Edith

AU - Grahn, Hanno

AU - Rybczinski, Meike

AU - Barten, Markus J

AU - Legros, Tim

AU - Bertoglio, Luca

AU - Schrage, Benedikt

AU - Westermann, Dirk

AU - Lapenna, Elisabetta

AU - Reichenspurner, Hermann

AU - Bernhardt, Alexander M

N1 - Copyright © 2019. Published by Elsevier Inc.

PY - 2020/6

Y1 - 2020/6

N2 - PURPOSE: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) stabilizes patients in refractory cardiogenic shock. However, ECMO-related complications strongly affect the outcome, especially if a long-term LVAD is needed.METHODS AND MATERIALS: We describe a new strategy in management of INTERMACS 1 patients consisting in early weaning from VA-ECMO with axillary Impella 5.0 as a bridge to LVAD implantation. Nine patients in two European centres are described.RESULTS: All patients were implanted with VA-ECMO for initial hemodynamic and metabolic stabilization. After a median time of 8 days, Impella 5.0 was implanted. Impella support allowed in all patients weaning from inotropes and from VA-ECMO (after a median time of 22 h). No patients had right ventricular failure after ECMO-weaning and most patients were mobilized and orally fed (88.9%) during Impella support. All patient underwent LVAD implantation after a median Impella time of 17 days. Only one patient had right-ventricular failure after LVAD implantation. All patients were discharged from hospital after a median time of 40 days.CONCLUSION: Early weaning from VA-ECMO with Impella 5.0 as a bridge to LVAD is a safe and effective strategy in management of INTERMACS 1 patients. This approach minimizes ECMO-related complications and allows patient mobilization and right ventricular function optimization before LVAD implantation.

AB - PURPOSE: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) stabilizes patients in refractory cardiogenic shock. However, ECMO-related complications strongly affect the outcome, especially if a long-term LVAD is needed.METHODS AND MATERIALS: We describe a new strategy in management of INTERMACS 1 patients consisting in early weaning from VA-ECMO with axillary Impella 5.0 as a bridge to LVAD implantation. Nine patients in two European centres are described.RESULTS: All patients were implanted with VA-ECMO for initial hemodynamic and metabolic stabilization. After a median time of 8 days, Impella 5.0 was implanted. Impella support allowed in all patients weaning from inotropes and from VA-ECMO (after a median time of 22 h). No patients had right ventricular failure after ECMO-weaning and most patients were mobilized and orally fed (88.9%) during Impella support. All patient underwent LVAD implantation after a median Impella time of 17 days. Only one patient had right-ventricular failure after LVAD implantation. All patients were discharged from hospital after a median time of 40 days.CONCLUSION: Early weaning from VA-ECMO with Impella 5.0 as a bridge to LVAD is a safe and effective strategy in management of INTERMACS 1 patients. This approach minimizes ECMO-related complications and allows patient mobilization and right ventricular function optimization before LVAD implantation.

KW - Adult

KW - Extracorporeal Membrane Oxygenation/instrumentation

KW - Female

KW - Follow-Up Studies

KW - Heart Failure/therapy

KW - Heart-Assist Devices

KW - Hemodynamics

KW - Humans

KW - Male

KW - Middle Aged

KW - Research Design

KW - Retrospective Studies

KW - Shock, Cardiogenic/therapy

KW - Ventricular Function, Right

U2 - 10.1016/j.jcrc.2019.12.028

DO - 10.1016/j.jcrc.2019.12.028

M3 - SCORING: Journal article

C2 - 32061461

VL - 57

SP - 259

EP - 263

JO - J CRIT CARE

JF - J CRIT CARE

SN - 0883-9441

ER -